DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Inhaled Liposomal Amikacin

Phase Three

Phase Three

Therapeutic Approach

Anti-Infective

Inhaled liposomal amikacin (Arikace™) is an antibiotic that is being used to treat chronic lung infections caused by nontuberculous mycobacteria (NTM). 

Status

A Phase 3 trial for the treatment of nontuberculous mycobacteria (NTM) was completed in 2015.

Sponsor

The program is sponsored by Insmed Incorporated and partially funded by Cystic Fibrosis Foundation Therapeutics. It is is being conducted within CFFT's Therapeutics Development Network.

Contact us about Inhaled Liposomal Amikacin >